Summary- A new market study, titled “Global Prostate Cancer Market Insights & Forecast with Potential Impact of COVID-19 2020-2024 “Market OverviewThe global prostate cancer market is anticipated to reach US$14.41 billion in 2024, witnessing growth at a CAGR of 4.62%, over the period 2020-2024.A few notable trends may include expansion of pharmaceutical industry, growing burden of prostate cancer and advancements in oncology.The global prostate cancer market can be categorized on the basis of cancer type, drug and therapy.According to drugs, the global prostate cancer market can be split into Enzalutamide, Abiraterone Acetate, Leuprorelin and other drugs.Whereas, in terms of therapy, the global prostate cancer market can be bifurcated into chemotherapy, targeted therapy, immunotherapy, hormonal therapy and other therapies.The fastest growing regional market is North America due to rising prevalence of prostate cancer in the region, highly competitive and developed medical sector, high investment in research and development activities for the development of newer immunotherapies and targeted drug therapies to treat various cancers.
Global Cancer Immunotherapy Market is expected to reach XX Billion by 2026 from 79.24 Billion in 2019 at CAGR of XX % (Detailed analysis of the market CAGR is provided in the report).The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters.Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments.The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.Global Cancer Immunotherapy MarketCancer immunotherapy (sometimes called immuno-oncology) is the artificial stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight cancer.It is an application of the fundamental research of cancer immunology and a growing subspeciality of oncology.However, stringent regulatory policies is a key restraining factor for market growth.The Hospital sub-segment is expected to gain the largest market share during the forecast period.The report helps in understanding Global Cancer Immunotherapy market dynamics, structure by identifying and analyzing the market segments and projecting the global market size.
Cancer Immunotherapy Market: An OverviewThe Global Cancer Immunotherapy Market size is forecast to surpass USD 153.03 billion in 2027 from USD 78.04 billion in 2019, delivering a CAGR of 10.1% over the forecast period.Get a sample copy of the report @ https://www.reportsanddata.com/sample-enquiry-form/1550Cancer Immunotherapy Market Dynamics A paradigm shift from traditional chemotherapies to immunotherapies has created a rewarding growth scope for the cancer immunotherapy industry.Immuno-oncology has exhibited encouraging results with lower toxicity and better survival rates.The continuing research and new approvals are expected to foster cancer immunotherapy market share over the forecast period.However, immunotherapy side effects can range from mild up to life-threatening cases owing to certain circumstances of the patients’ health.Cancer Immunotherapy Market: Key Players • Bristol-Myers Squibb • Celgene Corporation • Novartis International Ag, Amgen Inc. • Merck & Co. Inc. • Seattle Genetics Inc • Printegra, Janssen Global Services, LLC • Gristone Oncology, and Inc • Pfizer Inc. Impact of COVID-19 on Cancer Immunotherapy Market: After the COVID-19 outbreak, a serious concern among the medical profession was contemplating if using cancer immunotherapy in COVID-19 patients would produce to any complications or worsen their conditions.
Summary - A new market study, titled “Global Artificial Intelligence Diagnostics Market Growth (Status and Outlook) 2020-2025 ” has been featured on WiseGuyReports.According to this study, over the next five years the Artificial Intelligence Diagnostics market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019.In particular, this report presents the global revenue market share of key companies in Artificial Intelligence Diagnostics business, shared in Chapter 3.ALSO READ: https://www.einpresswire.com/article/529862428/artificial-intelligence-diagnostics-market-2020-global-analysis-industry-growth-current-trends-and-forecast-till-2025This report presents a comprehensive overview, market shares, and growth opportunities of Artificial Intelligence Diagnostics market by product type, application, key manufacturers and key regions and countries.This study specially analyses the impact of Covid-19 outbreak on the Artificial Intelligence Diagnostics, covering the supply chain analysis, impact assessment to the Artificial Intelligence Diagnostics market size growth rate in several scenarios, and the measures to be undertaken by Artificial Intelligence Diagnostics companies in response to the COVID-19 epidemic.Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.Radiology Oncology Neurology Cardiology Chest & Lungs Other Diagnosis TypesSegmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC CountriesThe report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.General Electric (GE) Co. (GE Healthcare) Zebra Medical Vision Ltd. Siemens AG (Siemens Healthineers) AliveCor, Inc. Imagen Technologies, Inc. Aidoc Medical Ltd. NovaSignal Corporation VUNO, Inc. Riverain Technologies, LLC IDx Technologies, Inc. OSP Lab Philips TessellaIn addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole.
Adrenocortical Carcinoma Treatment Research Report: By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), by Therapy (Radiation Therapy and Others), by End-User (Hospitals and Clinics and Others)—Forecast till 2023The global Adrenocortical Carcinoma Treatment Market is expected to grow steadily over the forecast period.It is estimated that the global Adrenocortical Carcinoma Treatment Market is expected to register a CAGR ~ 2.6 % with an anticipated market value of 678 million during the forecast period from 2018 to 2023.Adrenocortical carcinoma (ACC) is a rare and highly aggressive carcinoma.However, differentiation of benign and malignant tumor in the initial stages needs proper evaluation.These factors coupled with the lack of oncology experts may restrain the growth of the market during the forecast period.On a regional basis, the Adrenocortical Carcinoma Treatment Market in the Americas is anticipated to dominate the market during the forecast period.Moreover, higher demand for quality products and the availability of reimbursement policies are expected to contribute to the market growth in this region.Currently, the global Adrenocortical Carcinoma Treatment Market is dominated by several players.
The market growth is driven by growing adoption of targeted therapy over traditional therapy coupled with rising mAbs demand.Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-covid-19/1603Adroit Market Research report on global immuno oncology assays market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities, and challenges.The market has been studied for historic years from 2018, with the base year of estimation as 2019 and forecast from 2020 to 2028.The report covers the current status and future traits of the market at global as well as country level.Options involve testing circulating proteins in the blood using immunoassays; evaluating the blood 's cellular portion, including analyzing circulating tumor cells and/or circulating free DNA by flow cytometry; and PCR expression of tumor genesBrowse the complete report @ https://www.adroitmarketresearch.com/industry-reports/immuno-oncology-assays-marketNorth America currently holds the largest share in Immuno Oncology Assays market owing to the presence of significant number of major players across the region along with growing investments by the established firms.Furthermore, Asia Pacific is going to record growth at a faster pace on account of rising awareness levels of cancer, and growing interest of major giants to explore opportunities across emerging economies of India, and China in particular.The scope of the report is segmented into product, technology, indication, applications, and region.For Any Query on the Immuno Oncology Assays Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1603Key segments of the global immuno oncology assays marketProduct Overview, 2018-2028 (USD Billion)ConsumablesSoftwareTechnology Overview, 2018-2028 (USD Billion)ImmunoassayFlow CytometryPCRNext Generation SequencingIndication Overview, 2018-2028 (USD Billion)Lung CancerColorectal CancerOther CancersApplications Overview, 2018-2028 (USD Billion)ResearchClinical DiagnosticsRegional Overview, 2018-2028 (USD Billion)North AmericaS.CanadaEuropeGermanyUnited KingdomFranceSpainRest of EuropeAsia PacificChinaJapanIndiaRest of Asia PacificLatin AmericaBrazilMexicoRest of Latin AmericaMiddle East & AfricaGCCRest of Middle East and AfricaAbout Us :Adroit Market Research is an India-based business analytics and consulting company.
To order this detailed 485+ page report, please visit this link Key InclusionsA detailed assessment of the current market landscape, providing information on drug developer(s) (year of establishment, headquarters and size of the company), phase of development (marketed, clinical, preclinical, and discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of therapy (monotherapy and combination therapy), type of synlet target, target patient segment, key therapeutic area(s), target indication(s), and route of administration.In addition, the chapter includes a list of screening platforms that are being used by industry players to study synlet interactions between gene pairs.Detailed profiles of large players that are engaged in the development of synthetic lethality-based drugs (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed profiles of their respective lead drug candidates, and an informed future outlook.In addition, the chapter includes tabulated profiles of small-sized and mid-sized players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as location of headquarters, year of establishment, number of employees, and key members of the executive team), recent developments, along with descriptions of their synthetic lethality-based drug candidates.An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, posted during the period 2010-2019 (till May), highlighting the historical trend of tweets, most prolific contributors, frequently discussed synlet targets, popular disease indications and a multivariate tweet benchmark analysis.An analysis of close to 700 peer-reviewed scientific articles related to synthetic lethality, published during the period 2017-2019 (till May), highlighting the research focus within this niche industry segment.It includes an informed opinion on the key trends observed across the aforementioned publications, including information on target disease indications, synlet targets, and analysis based on various relevant parameters, such as study type (review article, research article and case report), research objective, year of publication, key research hubs, most popular authors, provision of grant support, and most popular journals (in terms of number of articles published in the given time period and journal impact factor).An analysis of various abstracts presented at the American Society of Clinical Oncology (ASCO) in the time period 2013-2019 (till May), highlighting several parameters, such as year of (abstract) publication, popular drugs, synlet targets, target cancer indications, popular authors, author designations, industry type (industry and academia) and most active organizations (in terms of number of published abstracts).In addition, this analysis features a multi-dimensional bubble chart analysis to assess the relative level of expertise of the key authors / researchers based on the number of publications, citation count and research gate score.An in-depth analysis of close to 750 grants that have been awarded to research institutes engaged in projects related to synthetic lethality, between 2014 and 2019 (till May), highlighting various important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers.It also features a detailed analysis on most popular synlet targets and target indications, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, grant type, number of synlet targets and number of indications under study.An analysis of the investments made into companies that have proprietary synthetic lethality-based drugs / screening platforms, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.An in-depth benchmark analysis of over 230 synlet targets identified from various credible sources (research publications, government fundings, clinical studies, recent news / tweets and abstracts presented in global conferences), highlighting targets that have already been validated in clinical studies, preclinical studies and early-stage research (cases where there is no lead (therapeutic) candidate being investigated).
Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.Roots Analysis is pleased to announce the publication of its recent study, titled, “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”.The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade.The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.In addition to other elements, the study includes:A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of molecule, type of therapy, type of synlet target, target patient segment, key therapeutic area(s), target indication(s), and route of administration.In addition, the chapter includes a list of screening platforms that are being used by industry players to study synlet interactions between gene pairs.Detailed profiles of players that are engaged in the development of synthetic lethality-based drugs, featuring a brief overview of the company, its financial information (if available), detailed profiles of their respective lead drug candidates, and an informed future outlook.An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, posted during the period 2010-2019 (till May), highlighting the historical trend of tweets, most prolific contributors, frequently discussed synlet targets, popular disease indications and a multivariate tweet benchmark analysis.An analysis of close to 700 peer-reviewed scientific articles related to synthetic lethality, published during the period 2017-2019 (till May), highlighting the research focus within this niche industry segment.An analysis of various abstracts presented at the American Society of Clinical Oncology (ASCO) in the time period 2013-2019 (till May), highlighting several parameters, such as year of (abstract) publication, popular drugs, synlet targets, target cancer indications, popular authors, author designations, industry type (industry and academia) and most active organizations (in terms of number of published abstracts).An in-depth analysis of close to 750 grants that have been awarded to research institutes engaged in projects related to synthetic lethality, between 2014 and 2019 (till May), highlighting various important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers.An analysis of the investments made into companies that have proprietary synthetic lethality-based drugs / screening platforms, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.An in-depth benchmark analysis of over 230 synlet targets identified from various credible sources (research publications, government fundings, clinical studies, recent news / tweets and abstracts presented in global conferences), highlighting targets that have already been validated in clinical studies, preclinical studies and early-stage research (cases where there is no lead (therapeutic) candidate being investigated).
Short read sequencing market is expected to gain market growth in the forecast period of 2020 to 2027.Data Bridge Market Research analyses the market to account to USD 23.15 billion by 2027 growing at a CAGR of 11.34% in the above-mentioned forecast period.This short read sequencing market report provides details of market share, new developments, product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market.Get Exclusive Sample Report: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-short-read-sequencing-marketMajor Market Players: Global Short Read Sequencing MarketThe major players covered in the short read sequencing market report are Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Illumina, Inc, GENEWIZ, GenScript., 10x Genomics., Macrogen Inc, QIAGEN, Agilent Technologies, Inc., BGI, Fasteris, General Electric, Eurofins Scientific, among other players domestic and global.Segmentation: Global Short Read Sequencing MarketBy Technology (Next- Generation Sequencing, Sanger Sequencing)By Product (Instruments, Consumables, Services)By Application (Oncology, Clinical Investigation, Reproductive Health, HLA Typing/Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Agrigenomics & Forensics, Consumer Genomics)By Workflow (Pre- Sequencing, Sequencing, Data Analysis)By End- User (Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, Other)By Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France)Focus of the reportCAGR values in the market for the forecast periodKey trends in the market placeMajor players and brandsHistorical and current market size and projection up to 2026.Detailed overview of parent marketChanging market dynamics of the industryReasons to Purchase this ReportThe segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast periodRegions/Countries that are expected to witness the fastest growth rates during the forecast periodThe latest developments, market shares, and strategies that are employed by the major market playersFor More Inquiry Contact us at: @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-short-read-sequencing-marketKey insights in the report:Complete and distinct analysis of the market drivers and restraintsKey Market players involved in this industryDetailed analysis of the Market SegmentationCompetitive analysis of the key players involvedAbout Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.Contact:Data Bridge Market ResearchUS: +1 888 387 2818 Related Reports:Parasitology Identification MarketOrchitis Treatment Market
Market HighlightsThe growing acceptance of Single-Photon Emission Computed Tomography (SPECT) accustomed by its technical advances is one of the major trends witnessed in the global SPECT market over the forecast period.Basically, these tracers are used to diagnose and predict outcomes in various disease states by monitoring the therapeutic effects.Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1339 The SPECT market is expected to witness tremendous growth owing to the new 99mtc labelled agents for visualizing biologically significant events, and integration of X-ray tomography (CT) In SPECT.However, challenges such as need for skilled professionals, and reimbursement issues, is likely to curb the market growth during the forecast period.SegmentationThe global Single-Photon Emission Computed Tomography (SPECT) market is segmented into type, application, end-users.The Single-Photon Emission Computed Tomography (SPECT) market, by type, the market is segmented into hybrid SPECT systems, and standalone SPECT systems.On the basis of application, the Single-Photon Emission Computed Tomography (SPECT) market is bifurcated into oncology, cardiology, neurology, and others.On the basis of end-user, the market is segmented into hospitals, diagnostic imaging centers, academic & research centers, and others.Regional AnalysisThe Americas is the largest in the market owing to the improving research infrastructure in the region, coupled with the rising awareness among patients and physicians for radioisotopes.
Market ScenarioAs per the data experts at Market Research Future (MRFR), the chronic lymphocytic leukemia treatment market was worth USD 7.9 Billion in 2017.Additionally, the market is expected to expand at a growth rate of 19% over the forecast period (2018-2023).Market Drivers and Key ChallengesChronic lymphocytic leukemia is considered to be one of the most common types of leukemia in adults.In general, one does not experience any symptoms due to chronic lymphocytic leukemia for a long period.However, the symptoms usually noted include fatigue, easy bruising, and swollen lymph nodes.Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6900 Generally, the most popular form of treatment for CLL is chemotherapy, whereas stem-cell transplant is for rare cases.The boost in cancer cases around the world, innovations in drug therapy, quick regulatory approval processes, and vigorous pipeline of drugs for chronic lymphocytic leukemia treatment are additional factors substantiating the growth of the chronic lymphocytic leukemia market.Having said that, the stunted level of awareness with regard to symptoms is expected to retard the market growth in the forthcoming years.However, growing research & development activities coupled with continuous technological developments in the field is presumed to augment the market growth to a large extent.Market SegmentationThe global chronic lymphocytic leukemia treatment market has been segmented on the basis of type, treatment, and end user.The market, in terms of the type, has been considered for indolent CLL and aggressive CLL.The market, treatment-wise, can be broken down into chemotherapy, targeted drug therapy, immunotherapy, and bone marrow transplant.The end users in the global market are hospitals & clinics, diagnostic laboratories, research institutes, and others.Prominent PlayersThe prominent vendors within the worldwide chronic lymphocytic leukemia treatment market include Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Genmab A/S, TG Therapeutics, Inc., Ziopharm Oncology, F. Hoffmann-La Roche Ltd, AbbVie Inc., Genentech, Inc., Gilead, Genzyme Corporation, ONO PHARMACEUTICAL CO., LTD., GlaxoSmithKline plc, CELGENE CORPORATION, Inc., Johnson & Johnson Services, Inc., and others.Regional InsightThe chronic lymphocytic leukemia treatment market is set to expand in the region of Europe, Asia Pacific, America, and the Middle East & Africa during the assessment period.Following a meticulous analysis of the global trends, the Americas has been identified as the leading region in the chronic lymphocytic leukemia treatment market.
Summary - A new Market study, titled “Global Enteral Feeding Devices Market Size study with COVID-19 Impact, by Type (Enteral Feeding Pumps, Enteral Feeding Tubes, Administration Sets, Enteral Syringes and Other), by Age Group (Adult and Pediatrics), by Application (Oncology, Gastroenterology, Neurology, Diabetes, Hypermetabolism and Others), by End- User (Hospital, Homecare Setting and Ambulatory Care Settings) and Regional Forecasts 2020-2027” has been featured on WiseGuyReports.Global Enteral Feeding Devices Market is valued approximately USD 3.0 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 6.8 % over the forecast period 2020-2027.Enteral feeding devices are commonly used to feed diets in elderly or bedridden patients suffering from chronic ailments, such as cancer, neurological disorders, gastrointestinal and inherited metabolic diseases.The current pandemic situation has increased the adoption of enteral feeding devices including feeding tubes and administration sets, which results to increase the demand for the market.The shift from parenteral to enteral nutrition, increasing incidence of preterm births, growing demand for enteral feeding in the home care sector and increasing prevalence of chronic diseases are the few factors responsible for growth of the market over the forecast period.For instance: on 01st December 2017, Fresenius Kabi AG opened the extension of its production plant in Mihla, Germany to improve the production of feeding tubes and giving sets, which are routinely used in hospitals, with an investment of about USD 12 million.
Biopharmaceuticals seeking stronghold in the global cancer cachexia market have adopted strategies that accelerate time-to-market of novel pharmaceutical agents, observes analysts at Transparency Market Research.Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=15482Top Players Adopt Strategies for Testing Multidisciplinary Combination TherapiesLeading players are entering into partnerships and mergers with, and acquisitions of organizations engaging in clinical trials.These strategies underpin the development of new multidisciplinary combination therapies, thereby aiding them to consolidate their shares.In an increasingly competitive market, companies that vie for sizable shares in the cancer cachexia market include Novartis, Merck & Co. Inc., Eli Lilly and Co., Aphios Corp., Alder BioPharmaceuticals Inc., and Aeterna Zentaris.Request a Sample of Animal Parasiticides Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S_id=15482Advancing Oncology Care Reflects Well on North America MarketAmong the various regions, the pipeline of pharmacologic agents is ripe in North America.This is bolstered mainly by presence of pipeline drugs in phase 3 clinical trial.Developing regions, notably Asia Pacific, have vast pool of patients with cancer.Of marked significance is understanding of myostatin/activin pathways, paving way for new avenues in the global cancer cachexia market.Request for Analysis of COVID19 Impact on Cancer Cachexia Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=15482Rich Drug Pipeline of Multiple Pharmacologic Agents boosts MarketThe cancer cachexia market stood at US$1.63 bn and is projected to garner a CAGR of 4.90% from 2017 to 2025.By the end of this assessment period, opportunities in the market will climb to US$2.51 bn.The growth of the global cancer cachexia market is fueled by vast research on using multiple agents for treating metabolic abnormalities in cachexia.
The study also encompasses valuable insights about profitability prospects, market size, growth dynamics, and revenue estimation of the business vertical.The study further draws attention to the competitive backdrop of renowned market contenders, including their product offerings and business strategies.The global market for G-protein coupled receptors has been segmented based on the product, assay type, and application.As per Market Research Future (MRFR) analysis, the global G Protein Coupled Receptors Market is expected to reach USD 3,100 million with a CAGR of 7.1% CAGR from 2017 to 2024 (forecast period).G-protein coupled receptors (GPCRs), also referred as seven-transmembrane domain receptors, 7-TM receptors, serpentine receptors, heptahelical receptors, and G-protein-linked receptors (GPLRs), are a broad family of receptor proteins that detect molecules outside the cell and enable internal signal transduction pathways and, ultimately, cellular responses.Coupled with G proteins, they are called seven-transmembrane receptors because they pass across the cell membrane seven times.Market DynamicsThe growth of the global market for G-protein coupled receptors (GPCR) is driven by a variety of factors, such as increased use of G-protein combined receptors in drug disclosure and advancement forms, and an increase in the number of drugs in clinical and preclinical studies targeting these receptors.However, the high cost of maintaining GPCR cell lines and strict government policies is expected to reduce the global market growth for G-protein coupled receptors.Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/8356SegmentationThe global market for G-protein coupled receptors has been segmented based on the product, assay type, and application.Based on the product, the market has been divided into cell lines, detection kits, cell culture reagents, ligands, and others.The segment for detection kits are plausible to be the fastest during the evaluation period as they are ready to use kits that include all cells and reagents to conduct functional GPCR assay in live cells, thereby pushing the growth of the global G protein coupled receptor market.Based on assay type, the global G-protein coupled receptor market has been segmented into functional calcium assays, cGMP assays, internalization assays, GTP gamma S binding assays, cAMP functional assays, ß-Arrestin Functional Assays, and others.Calcium functional assays are the strongest segment, with numerous advantages, such as user configurability and ease in estimating calcium flux, thereby driving this segment’s growth in the GPCR market.Based on the application, the global G protein coupled receptors market has been segmented into the cardiovascular system, oncology, respiratory system, immunology, central nervous system, and others.
SHIRLEY, NY – Sep 8, 2020 - With a high reputation for sequencing, microarray analysis, library construction and genotyping, CD Genomics provides reliable services to pharmaceutical and biotechnology companies as well as academia and government agencies.These days, the product manager of CD Genomics announced that the company has recently optimized NGS oncology panels, which can meet the most challenging research processes.Cancer is a genetic disease, which is induced by the accumulation of harmful DNA mutations in cells.At present,it has been elucidated that the mechanisms of inducing abnormal cell proliferation, differentiation and cancer production are mainly categorized as follows: activating dominant transforming proto-oncogenes by translocations and mutations, inactivating tumor suppressor gene by mutations, and disordering the DNA repair genes.There are two basic types of gene mutations, namely germline mutations and somatic mutations,depending on where the mutation occurs in the tissue.Germline mutations are genetic changes that can be inherited from our parents that cause cancer.If germline mutations occur in sperm cells or egg cells, it may be passed on from generation to generation.Cancers caused by germline mutations are called hereditary cancers, accounting for 5% to 20% of all cancers.Somatic mutations are the most common cause of cancer.
The global Oncology Biosimilars market is likely to gain momentum in the coming years and exhibit a CAGR of 29.4% says a recent report published by Fact.MR.The impact of the COVID-19 pandemic on the global Oncology Biosimilars market is thoroughly discussed in the report.The imposition of lockdown by the governments of all nations worldwide resulted in huge losses for most businesses.However, the healthcare sector gained promising revenues on account of the increasing number of patients, rising demand for safety kits, and growing panic and tension amongst the common man.Several institutions have invested heavily and engaged in deep research and development so as to come up with an antidote to fight the novel coronavirus.Request to View Sample of Research Report @ https://www.factmr.com/connectus/sample?flag=S_id=4800The report on the Oncology Biosimilars market elaborates the possibility of trading and investment and certain tricks up the sleeve for gaining a positive edge in the market during the forecast period.
Summary - A new market study, titled “COVID-19 Impact on Global IV and Oral Iron Drugs Market Size, Status and Forecast 2020-2026 ” has been featured on WiseGuyReports.This report focuses on the global IV and Oral Iron Drugs status, future forecast, growth opportunity, key market and key players.The study objectives are to present the IV and Oral Iron Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South AmericaALSO READ: https://wiseguyreports.wordpress.com/2020/07/21/iv-and-oral-iron-drugs-market-2020-overview-trend-and-forecast-to-2025/The key players covered in this study Daiichi Sankyo Company Vifor Pharma Akebia Therapeutics Allergan AMAG Pharmaceuticals AOP Orphan Pharmaceuticals Pharmacosmos Sanofi Shield Therapeutics AZAD Pharma Cirondrugs MEDICE Pfizer Salveo Lifecare Sunny PharmaceuticalMarket segment by Type, the product can be split into Oral Iron Drug IVIron Drugs Market segment by Application, split into Nephrology OBGYN Surgeries Gastroenterology Oncology Heart failure (HF)Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South AmericaThe study objectives of this report are: To analyze global IV and Oral Iron Drugs status, future forecast, growth opportunity, key market and key players.To present the IV and Oral Iron Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.In this study, the years considered to estimate the market size of IV and Oral Iron Drugs are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year.
Summary - A new market study, titled “Global Next-Generation Sequencing (NGS) Services MarketResearch Report 2020”has been featured on WiseGuy Reports.About Online GamblingFactors such as declining price of sequencing, the high cost of sequencing infrastructure, the need for skilled professionals for efficient NGS sample preparation and analysis, and technological advancements in the field of sequencing are driving the growth of this market.Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022.The global Next-Generation Sequencing (NGS) Services market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.This report focuses on Next-Generation Sequencing (NGS) Services volume and value at global level, regional level and company level.From a global perspective, this report represents overall Next-Generation Sequencing (NGS) Services market size by analyzing historical data and future prospect.Regionally, this report categorizes the production, apparent consumption, export and import of Next-Generation Sequencing (NGS) Services in North America, Europe, China, Japan, Southeast Asia and India.For each manufacturer covered, this report analyzes their Next-Generation Sequencing (NGS) Services manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.The following manufacturers are covered: BGI Illumina Perkinelmer Eurofins Scientific Gatc Biotech Macrogen Qiagen Genotypic Technology Genewiz Dna Link Takara Scigenom Labs Novogene Personalis ALSO READ :https://icrowdnewswire.com/2019/11/04/next-generation-sequencing-ngs-services-2019-industry-growth-share-trends-demand-analysis-and-forecast-to-2025/Segment by Regions North America Europe China Japan Southeast Asia IndiaSegment by Type Targeted RNA-Seq ExomeSegment by Application Diagnostics Oncology Drug Discovery Agriculture FOR MORE DETAILS: https://www.wiseguyreports.com/reports/4462163-global-next-generation-sequencing-ngs-services-market-professionalAbout Us:Wise Guy Reports is part of the Wise Guy Research Consultants Pvt.